In times of uncertainty, one of the best ways to have some peace is to probably go back and reexamine again some of the fundamentals and dataNfacts. I personally ignored all other signed/not-signed/promised deals or memorandums (at this pre-IPO stage), and ONLY focus on GMV's US IDTF (GMEDx) development, its revenues (published in the Quarterlys and Annual reports) and its consistency since 2018. Below are just some snippets:
https://hotcopper.com.au/threads/ann-g-medical-continues-rapid-growth-in-usa.5131621/
Data:
Patients monitored in the entire CY2018: 10820.
Patients monitored in from Jan 2019 to Oct 2019: 23940. (when university hospitals were started to be involved.)
https://hotcopper.com.au/threads/ann-four-us-university-hospitals-deploy-gmvs-idtf-platform.5504661/
Data:
Patients monitored in the entire CY2019: 27946. (if deduct 23940 from Jan2019 to Oct2019, Nov2019+Dec2019
patients number was 4006.)
Total CY2019 revenue from IDTF activities: US$5.42m
From above we can get an approximate IDTF revenue per patient: US$5.42m/27946 = US$194 ~=US$200
The above figures are reassured again in the following pictures.
https://hotcopper.com.au/threads/ann-update-on-continued-expansion-of-idtf-platform-in-usa.5517116/
https://hotcopper.com.au/threads/ann-ten-us-university-hospitals-now-deploying-idtf-platform.5574839/
Data:
In several ANNs GMV says it is confident that it will meet three-fold increase in patient numbers by the end of CY2020.
From the above graph, from Jan 2020 to July 2020 total patients monitored approximately: ~13100.
To achieve the claimed three-fold increase which will be 27946 x 3 = 83838 say ~= 80000, Aug 2020 to Oct 2020 has to have a significant increase in patient numbers, and Nov2020 + Dec2020 also has to be way more than last year's number 4006.
Based on above, i take a very conservative patient number figure for CY2020 instead of 80000, a two-fold of CY2019 which will be
approximately 27946 x 2 ~= 56000.
Though the following Anns reassured the 3-fold increase:
https://hotcopper.com.au/threads/ann-new-revenue-stream-added-to-idtf-platform.5585315/
I will still use my conservative patient number for CY2020: 56000, and average revenue per patient to be ~US$200.
Therefore the total revenue of CY2020 from IDTF only will be:
56000 x US$200 ~= US$11.2m
After consolidation: total SOI ~= 46.7m (excluding option conversion) + IPO 5,750,000 shares = 52.5m total plus options.
Apply IPO price/revenue ratio:
x10 -> MCap US$112m -> $112m/52.5m = US$2.13; (worst case scenario)
x15 -> MCap US$168m -> $168m/52.5m = US$3.2
x20 -> MCap US$168m -> $168m/52.5m = US$4.3
If the claimed total patient numbers by the end of CY2020 are actually achieved, say 80000:
Then the total revenue of CY2020 from IDTF only will be:
80000 x US$200 ~= US$16.0m
Apply IPO price/revenue ratio:
x10 -> MCap US$160m -> $112m/52.5m = US$3.0;
x15 -> MCap US$240m -> $240m/52.5m = US$4.6;
x20 -> MCap US$320m -> $320m/52.5m = US$6.0 (the targeting IPO price).
Anything beyond the estimated numbers above will all be extra extra bonuses.
Question to myself:
Will these patient numbers reduce or disappear suddenly/dramatically after 2020 (like other disappeared old deals) as well as the revenues from IDTFs? The answer is a big NO.
So probably just give them a bit more time to sort things out. I am personally still at peace.
- Forums
- ASX - By Stock
- GMV
- GMVD - NASDAQ IPO
GMVD - NASDAQ IPO, page-457
-
- There are more pages in this discussion • 1,475 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online